Skip to main content
RIGL logo

RIGL · Rigel Pharmaceuticals Inc

Track RIGL — free
$42.53 -0.39 (-0.91%) At close · Nov 18
Market Cap
$800.84M
Shares
18.83M
Volume · Nov 18 304.84K Avg daily vol (3M) 252.93K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$42.53 Open$42.79 Day$42.03–43.88 52W close$25.44–51.45 Avg vol 30d240K Short int2.5M · 13.5% of shares · 12.9d Short vol39% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Mar 2, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 17
Investor event
Vepenew Sales Reach 6.6 Million in First Six Weeks

Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.

7 source passages
The deal closed in June. In the first six weeks, it launched mid-August. We were able to achieve 6.6 million in sales, a really impressive number. This past quarter, we achieved 72 million in net product sales, our largest quarterly sales number ever. R289 is our IRAC-1 and 4 inhibitor in development in a Phase 1b study for relapse refractory lower-risk MDS. We will have updated data on the dose expansion phase at the ASH meeting in December in a few weeks. Our plan is to start the registrational study in 2027 with FDA concurrence on this. Open the document at this passage
Nov 5
Earnings call
Vepenu launch drives 13% product sales growth

Rigel generated $72.3 million in net product sales for the third quarter of 2026, up 13% year-over-year, including $6.6 million from Vepenu.

3 source passages
our net product sales were $72.3 million for the third quarter of 2026, an increase of 13% compared to the third quarter of 2025, primarily driven by the addition of Vepinu during the third quarter. Vepenu net product sales of $6.6 million, reflecting approximately six weeks of commercial availability. Rigel's Open the document at this passage
Nov 5
Current report 8-K
VEPPANU generates $6.6 million in initial sales

Rigel reported third-quarter total revenues of $80.9 million and net income of $13.2 million, while VEPPANU generated $6.6 million in initial net product sales. It updated the 2026 revenue outlook to approximately $290 to $295 million, excluding VEPPANU.

Financial results
5 source passages
For the third quarter ended September 30, 2026, total revenues were $80.9 million, consisting of $72.3 million in net product sales and $8.6 million in contract revenues from collaborations. Rigel reported net income of $13.2 million, or $0.70 basic and $0.65 diluted per share, compared to $27.9 million, or $1.55 basic and $1.46 diluted per share, for the same period of 2025. Rigel announced that VEPPANU (vepdegestrant) became commercially available in the U.S. on August 13, 2026, generating $6.6 million in net product sales in the third quarter. Rigel has updated its 2026 total revenues guidance to approximately $290 to $295 million, from the previous range of approximately $285 to $295 million, which includes: The above revenue guidance excludes VEPPANU. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
VEPPANU launches with $6.6 million in initial sales

VEPPANU generated $6.6 million in initial net product sales from its August 13, 2026 launch through September 30, 2026, while nine-month TAVALISSE sales rose 15% to $130.6 million.

Revenue $80.89M ▲ 16.5% Net income $13.19M ▼ 52.7% Diluted EPS $0.65 ▼ 55.5%
Read from the MD&A section
2 source passages
VEPPANU is our fourth FDA-approved product which we began commercializing on August 13, 2026, with initial net product sales of $6.6 million from launch through September 30, 2026. TAVALISSE net product sales for the nine months ended September 30, 2026 were $130.6 million, an increase of $17.4 million, or 15%, compared with $113.3 million for the same period in 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$288.21M
Trailing 12 months
Net income (TTM)
$307.19M
Trailing 12 months
Revenue growth YoY
+16.5%
Year over year
Operating margin
26.3%
Trailing 12 months
P / E (TTM)
2.6
Trailing earnings · reciprocal yield 37.8%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$101.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.7%
Year over year · more shares
Price change (1Y)
-8.0%
Trailing year
Short interest
13.5%
Latest settlement · 12.9 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26

TL;DR. Rigel reported Q2 net product sales of $67.0 million (+14% YoY) and net income of $17.3 million, in-licensed and is preparing the mid-August U.S. launch of VEPPANU, and raised its 2026 total revenue guidance to $285–$295 million while reiterating an expected full-year profit.

Bullish
  • + Net product sales rose 14% YoY to $67.0 million in Q2 2026.
  • + TAVALISSE net product sales grew 18% YoY to $47.4 million.
  • + REZLIDHIA net product sales grew 27% YoY to $8.9 million.
  • + Rigel raised 2026 total revenue guidance to approximately $285–$295 million from the prior $275–$290 million range.
  • + VEPPANU in-license expands commercial portfolio, with U.S. commercial availability expected in mid-August.
  • + Company continues to anticipate positive full-year 2026 net income while funding new and existing programs.
Bearish
  • − Q2 net income fell to $17.3 million from $59.6 million a year ago, due largely to a prior-year $40.0M Lilly collaboration release.
  • − GAVRETO net product sales declined 10% YoY to $10.7 million.
  • − Total costs and expenses rose 36% YoY to $55.1 million, driven by higher personnel, R&D, and Arvinas/Pfizer-license costs.
  • − Cash, cash equivalents and short-term investments fell to $95.3 million at June 30, 2026 from $155.0 million at December 31, 2025, partly reflecting a $70.0 million upfront payment to Arvinas and Pfizer.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg −10%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 66%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −13%
trailing
6-month return +39%
trailing
YTD return −1%
this year
Relative strength +43%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $47 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.47% of shares out · ▼ -7.2% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
170 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Excellent
Revenue growth +64%
Y/Y
EPS growth +1868%
Y/Y
Free cash flow $75.2M
Valuation P/E 2.6
below peers
Balance sheet $11.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −50%
past year
ATR 5.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 5, 2026
2026 Outlook (full year 2026)
Total revenues Raised $290M – $295M
Aug 4, 2026 $285M – $295M changed to Nov 5, 2026 $290M – $295M
prior FY $294.28M midpoint −0.6% Y/Y
Net product sales, excluding VEPPANU Lowered $255M – $260M
Aug 4, 2026 $255M – $265M changed to Nov 5, 2026 $255M – $260M
Contract revenues from collaborations $35M
2026
Contract revenues Raised $35M
Aug 4, 2026 $30M changed to Nov 5, 2026 $35M
Previous outlook earlier release · from the 8-K filed May 5, 2026

Still-open targets the latest release did not restate under the same label.

Net product sales · full year 2026 $255M – $265M
Guided vs delivered · last 1 settled
Total revenue full year 2025
guided $285M – $290M
$294.28M Beat +2.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
−10% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
66% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $47 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
13.47% of shares out · ▼ -7.2% MoM · 12.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
170 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $25 Now $43 · 66% Range high $51
vs 200-day avg +13% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cencora, Inc. 21% the three months ended June 30, 2026 filing —
GAVRETO net product sales $20.3M the six months ended June 30, 2026 —
McKesson Corporation 46% the three months ended June 30, 2026 filing —
REZLIDHIA net product sales $17M the six months ended June 30, 2026 —
TAVALISSE net product sales $84.7M the six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RIGL
Rigel Pharmaceuticals Inc
this stock
$800.84M -0.7% +64.1% 2.6 13.5%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
170
% held
93.9%
Net QoQ
+1.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
203
View
Short & Settlement
Short Interest Falling
Shares short
2.5M
Days to cover
12.9d
Change
-197.1K sh
View
Short Volume
Short vol %
39%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
6
Value
$304
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
33.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$294.3M
Net income (FY)
$367.0M
EPS diluted
$19.48
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
20

Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.

View
Proposed Sales
Value
$87.5K
Shares
2.5K
Filed
Jun 22, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Rigel to Present at the Jefferies…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
RIGL -4.5% -13.0% +39.5% -17.1% -0.7%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -0.6% -7.4% +43.0% -13.7% -7.8%
Key facts CIK 1034842 CUSIP 766559702 13F (30d) 182 filings 156 filers Visit website Investor relations